Globus Medical, Inc. (NYSE:GMED) is one of the

8 Best Debt Free Stocks to Buy Right Now. On March 18, 2026, Wells Fargo assumed coverage of Globus Medical, Inc. (NYSE:GMED) with an Overweight rating and a $104 price target, while maintaining its rating, price target, and estimates.

Last month, Globus Medical, Inc. (NYSE:GMED) reported fourth-quarter EPS of $1.28, above the 96c consensus estimate, with revenue of $826.4M compared to the $803.29M consensus. Chief Executive Officer Keith Pfeil said momentum “accelerated in the fourth quarter,” pointing to double-digit sales and earnings growth and expansion across the company’s portfolio, including its spine business, supported by disciplined execution. Pfeil added that the company is focused on sustaining growth through product launches, expanding its sales force, and improving outcomes through its surgical ecosystem.

Copyright: nimon / 123RF Stock Photo

Globus Medical, Inc. (NYSE:GMED) raised its FY26 EPS outlook to $4.40-$4.50 from $4.30-$4.40, above the $4.24 consensus, and expects FY26 revenue of $3.18B-$3.22B compared to the $3.16B consensus.

Globus Medical, Inc. (NYSE:GMED) develops and commercializes healthcare solutions for musculoskeletal disorders globally.

While we acknowledge the potential of GMED as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.